A Biomimetic Micro‐Nano System Maximizing ‘Active Transport and Retention’ Effect in Solid Tumors
Source abstract
Abstract
ABSTRACT The Active Transport and Retention (ATR) principle offers a new strategy to enhance tumor entry of nanodrugs via transcytosis. However, its application is limited by poor tumor‐homing, endothelial polarized efflux, and uncontrollable transcytosis of the nanodrug. Herein, we construct a bio‐mimetic micro‐nano system (PG@BAM‐L RC ) comprising nanoliposomes (L RC ) and berbamine (BAM) within platelet‐derived microcarrier (PG), leveraging PG's tumor‐homing ability and MMP‐9 responsive remodeling for tumor‐specific cargo release. Thereafter, BAM selectively promotes basal transendothelial transport of L RC toward the tumor by modulating apical recycling endosomes. While R8 promotes the cellular uptake, the arginine‐lysine‐lysine‐arginine‐cysteine (Cys) ligand facilitates Golgi‐targeted transendothelial transport of L RC, bypassing the endo‐lysosome pathway. Once inside tumor cells, furin‐mediated Cys‐cleavage halts transcytosis, yielding superior intracellular drug retention compared to the non‐cleavable Cys counterpart (L RC’ ). Four murine tumor models are established, demonstrating high heterogeneity in collagen density, vascularity, and EPR effects. An orthotopic pancreatic tumor, characterized by minimal EPR effect, is selected to demonstrate the ATR effect of PG@BAM‐L RC . PG@BAM‐L RC loaded with BAY‐872243 exhibits exceptional tumor accumulation and therapeutic outcome compared to L RC, PG@L RC without BAM, and PG@BAM‐L RC . Collectively, this study establishes PG@BAM‐L RC as a robust tumor‐targeting system leveraging the ATR mechanism while addressing tumor heterogeneity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy University of Auckland Auckland New Zealand
School of Pharmacy China Pharmaceutical University Nanjing P. R. China
Department of Molecular Medicine and Pathology University of Auckland Auckland New Zealand
Funding
China Scholarship Council · Cancer Society of New Zealand
References (47)
Show source-provided references
1. 10.1016/j.jconrel.2014.03.03010.1016/j.jconrel.2014.03.030 ↗
2. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
3. 10.1016/j.addr.2022.11444910.1016/j.addr.2022.114449 ↗
4. 10.1038/s44222-024-00203-310.1038/s44222-024-00203-3 ↗
5. 10.1038/s41565-023-01323-410.1038/s41565-023-01323-4 ↗
6. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
7. 10.1038/s44222-024-00154-910.1038/s44222-024-00154-9 ↗
8. 10.1038/s44222-024-00165-610.1038/s44222-024-00165-6 ↗
9. 10.1016/j.biomaterials.2020.11990210.1016/j.biomaterials.2020.119902 ↗
10. 10.1016/S0955-0674(00)00120-410.1016/S0955-0674(00)00120-4 ↗
11. 10.1016/j.addr.2007.06.00810.1016/j.addr.2007.06.008 ↗
12. 10.1016/j.addr.2022.11448010.1016/j.addr.2022.114480 ↗
13. 10.1021/acsnano.5b0558310.1021/acsnano.5b05583 ↗
14. 10.1002/adma.20170430710.1002/adma.201704307 ↗
15. 10.1016/j.jconrel.2023.01.02610.1016/j.jconrel.2023.01.026 ↗
16. 10.1016/j.jconrel.2022.09.03610.1016/j.jconrel.2022.09.036 ↗
17. 10.1182/blood-2004-08-298010.1182/blood-2004-08-2980 ↗
18. 10.3390/pharmaceutics1412261410.3390/pharmaceutics14122614 ↗
19. 10.1155/2022/259296210.1155/2022/2592962 ↗
20. 10.4048/jbc.2011.14.2.8810.4048/jbc.2011.14.2.88 ↗
21. Mechanisms of Receptor Shedding in Platelets
22. 10.1039/D0TB02848G10.1039/D0TB02848G ↗
23. 10.1002/psc.340810.1002/psc.3408 ↗
24. 10.1016/j.biomaterials.2016.01.06110.1016/j.biomaterials.2016.01.061 ↗
25. 10.1038/aps.2009.1910.1038/aps.2009.19 ↗
26. 10.1016/j.ejphar.2021.17467910.1016/j.ejphar.2021.174679 ↗
27. 10.1074/jbc.270.47.2839710.1074/jbc.270.47.28397 ↗
28. 10.1074/jbc.M70938720010.1074/jbc.M709387200 ↗
29. 10.1186/s40170-015-0138-010.1186/s40170-015-0138-0 ↗
30. 10.1208/s12249-019-1485-x10.1208/s12249-019-1485-x ↗
31. 10.2217/nnm-2018-051010.2217/nnm-2018-0510 ↗
32. 10.1016/j.mtbio.2022.10021210.1016/j.mtbio.2022.100212 ↗
33. 10.1371/journal.pone.004464010.1371/journal.pone.0044640 ↗
34. 10.1007/s00232-006-0080-810.1007/s00232-006-0080-8 ↗
35. 10.3390/molecules1310246210.3390/molecules13102462 ↗
36. VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer
37. 10.1186/s13058-017-0801-110.1186/s13058-017-0801-1 ↗
38. 10.1038/s41563-023-01630-010.1038/s41563-023-01630-0 ↗
39. 10.1097/00001721-199711000-0000610.1097/00001721-199711000-00006 ↗
40. 10.1038/s41388-018-0555-y10.1038/s41388-018-0555-y ↗
41. 10.1016/j.colsurfb.2017.07.01410.1016/j.colsurfb.2017.07.014 ↗
42. 10.1021/acsami.3c1023710.1021/acsami.3c10237 ↗
43. 10.1007/s11095-021-02988-z10.1007/s11095-021-02988-z ↗
44. 10.1021/acsami.6b0082110.1021/acsami.6b00821 ↗
45. 10.1016/B978-012372551-6/50066-310.1016/B978-012372551-6/50066-3 ↗
46. 10.1002/cam4.11210.1002/cam4.112 ↗
47. 10.1038/sj.bjp.070485210.1038/sj.bjp.0704852 ↗